About UCSF Search UCSF UCSF Medical Center

Margaret A. Tempero, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
tempero_margaret

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF
Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science

Phone: (415) 353-9888 (appts)
Box 1770, UCSF
San Francisco, CA 94143-1770

View on UCSF Profiles


Additional Websites


Education

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology


Professional Experience

  • 1983-1987
    Asst. Prof. of Med., Dept. of Internal Medicine, University of Nebraska Medical Center (UNMC), Omaha, NE
  • 1987-1994
    Associate Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1985
    Assistant Professor (Courtesy), Eppley Institute for Cancer Research, Omaha, NE
  • 1994-1999
    Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1999
    Chief of Oncology/Hematology, V.A. Medical Center, Omaha, NE
  • 1997-1999
    Interim Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1995-1999
    Deputy Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1998-2003
    Member, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 1999-present
    Member, Scientific Advisory Board, Pancreatic Cancer Action Network (PanCAN)
  • 2000- 2007
    Chief of Medical Oncology, UCSF School of Medicine
  • 2000- 2012
    Deputy Director, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2000-present
    Professor of Medicine, UCSF School of Medicine
  • 2003-2004
    President, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 2004-present
    Member, Scientific Advisory Board, V Foundation
  • 2012-present
    Member, Mayo Clinic Annual SPORE Scientific Retreat
  • 2012-present
    Director, UCSF Pancreas Center
  • 2012-present
    Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
  • 2013-present
    Member, External Advisory Board, University of Alabama at Birmingham/University of Minnesota Pancreatic SPORE

Selected Publications

  1. Tempero M. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953.
    View on PubMed
  2. Tempero M. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845.
    View on PubMed
  3. Tempero M. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May 1; 12(5):603.
    View on PubMed
  4. Tempero M. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr 1; 12(4):449.
    View on PubMed
  5. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing Doublets Plus Bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View on PubMed
  6. Tempero M. JNCCN Going Forward. J Natl Compr Canc Netw. 2014 Mar 1; 12(3):301.
    View on PubMed
  7. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
    View on PubMed
  8. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5.
    View on PubMed
  9. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26.
    View on PubMed
  10. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204.
    View on PubMed
  11. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 1; 19(3):538-40.
    View on PubMed
  12. Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64.
    View on PubMed
  13. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405.
    View on PubMed
  14. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
    View on PubMed
  15. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81.
    View on PubMed
  16. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):703-13.
    View on PubMed
  17. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3.
    View on PubMed
  18. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jul; 22(7):1500-6.
    View on PubMed
  19. Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5.
    View on PubMed
  20. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017.
    View on PubMed

Go to UCSF Profiles, powered by CTSI